Sight Sciences (SGHT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

For the quarter ended March 2025, Sight Sciences, Inc. (SGHT) reported revenue of $17.51 million, down 9.1% over the same period last year. EPS came in at -$0.28, compared to -$0.33 in the year-ago quarter.

The reported revenue compares to the Zacks Consensus Estimate of $16.53 million, representing a surprise of +5.95%. The company delivered an EPS surprise of +3.45%, with the consensus EPS estimate being -$0.29.

While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine their next move, some key metrics always offer a more accurate picture of a company's financial health.

Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.

Here is how Sight Sciences performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:

• Revenue- Dry Eye: $0.39 million compared to the $0.23 million average estimate based on three analysts. The reported number represents a change of -60.9% year over year.
• Revenue- Surgical Glaucoma: $17.11 million versus $16.23 million estimated by three analysts on average. Compared to the year-ago quarter, this number represents a -6.3% change.
• Gross Profit - Dry Eye: $0.28 million versus the two-analyst average estimate of $0.07 million.
• Gross Profit - Surgical Glaucoma: $14.82 million versus $14.09 million estimated by two analysts on average.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research